Process Development of the Soft Histone Deacetylate Enzyme Inhibitor SHP-141: Acylation of Methyl Paraben and Suberyl Hydroxamic Acid Formation

SHP-141 (<b>1</b>) is a hydroxamic acid-based inhibitor of histone deacetylase enzymes which is under development for the treatment of cutaneous T-cell lymphoma. The original synthesis of <b>1</b> involved five synthetic steps beginning with suberic acid monomethyl ester. Final deprotection of the <i>O</i>-benzyl hydroxamate moiety using hydrogen and palladium catalyst mandated the use of metal scavengers to reduce palladium levels to within International Council for Harmonisation (ICH) guidance. Owing to the sensitivity of <b>1</b> toward self-condensation and the potential for N–O bond cleavage under hydrogenolytic conditions, we developed an alternative route to <b>1</b> which avoids Pd-mediated hydrogenation and prolonged metal scavenger treatment. This two-step process employs readily available suberic acid and methyl paraben and has successfully delivered multiple kilograms of <b>1</b> for clinical use. Importantly, crude <b>1</b> was stabilized for recrystallization in acetonitrile (ACN) solution by the addition of 0.1% citric acid and 4% water. Additionally, the filtration and drying of suitably sized aggregates of <b>1</b> with high purity (100 area%) was accomplished via temperature cycling of the <b>1</b>/ACN solution